Novo Nordisk Emphasizes Levemir “Predictability”
This article was originally published in The Pink Sheet Daily
Executive Summary
Planned second quarter launch would be nearly one year after FDA approval.
You may also be interested in...
Novo Nordisk Seeks To Block Sale Of Exubera, Claims Patent Infringement
The insulin maker says Pfizer's Exubera infringes Novo's patents covering inhaled insulin.
Novo Nordisk Seeks To Block Sale Of Exubera, Claims Patent Infringement
The insulin maker says Pfizer's Exubera infringes Novo's patents covering inhaled insulin.
Sanofi Loses Preliminary Injunction Bid Against Novo’s Levemir Promotional Materials
New Jersey federal court finds that Novo Nordisk’s claims regarding the insulin injection’s duration of effect and predictability are not literally false.